Patients after myocardial infarction with chronic heart failure with preserved left ventricular ejection fraction: the issue of prescribing beta blockers. The results of a 2-year prospective study



如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Aim. To study a 2-year catamnesis in patients with myocardial infarction (MI) with heart failure (HF) with preserved LVEF who received/did not receive beta-blockers (ВВ).

Materials and methods. 127 MI patients aged 53 (48; 60) years with preserved LVEF were included. On the 4th-9th day of MI, after 12 and 24 months, echocardiography with assessment of global longitudinal deformation (GLS), multi-day monitoring of the electrocardiogram (MMECG), the level of N-terminal propeptide of natriuretic hormone was determined, and a 6-minute walking test was performed. The end point was considered to be the progression of HF over the next 2 years.

Results. 29 (23%) patients did not receive BB due to hypotension and bradycardia – the "without BB" group, the other 98 (77%) who received BB formed the "BB" group.  In the "BB" group, by the 2nd year of the post-infarction period, there was an increase in indexed indices of final diastolic and systolic volumes, a decrease in LVEF by 3.1% (p=0.00077) and GLS by 2.4% (p=0.0002), in the "without BB" group, these parameters remained stable.

In patients of the BB group, a decrease in chronotropic load on the myocardium and an increase in the circadian index were recorded while maintaining its rigid level. In the group of patients "without BB", an increase in chronotropic load and normalization of the circadian rhythm profile were noted by 12 months after MI.

The number of patients with progressive HF over 2 years of follow-up in the "BB"/"without BB" groups did not differ: in 21% and 24%, respectively (RR=0.659 (95% 0.35-1.243)

Conclusion. In the group of patients with HF with preserved LVEF who did not take BB, a more stable state of the volume and deformation characteristics of the myocardium was noted for 2 years after MI, normalization of the circadian heart rhythm profile was observed, and no significant differences in the frequency of HF progression were found.

全文:

受限制的访问

作者简介

Elena Averyanova

Penza State University

Email: averyanova-elena90@bk.ru
ORCID iD: 0000-0001-9925-2096

кандидат медицинских наук, доцент кафедры "Терапия"

俄罗斯联邦, Krasnaya str., 40, Penza, 440026, Russia

Angelina Chernova

Penza State University

Email: angelinakorneeva170498@gmail.com
ORCID iD: 0009-0002-7957-8034

аспирант очной формы обучения кафедры «Терапия»

俄罗斯联邦, Krasnaya str., 40, Penza, 440026, Russia.

Olga Vershinina

Penza State University

Email: poloz.ol@yandex.ru
ORCID iD: 0000-0002-4127-6607

аспирант очной формы обучения кафедры «Терапия»

俄罗斯联邦, Krasnaya str., 40, Penza, 440026, Russia.

Valentin Oleynikov

Penza State University

编辑信件的主要联系方式.
Email: v.oleynikof@gmail.com
ORCID iD: 0000-0002-7463-9259

доктор медицинских наук, профессор, заведующий кафедрой «Терапия»

俄罗斯联邦, Krasnaya str., 40, Penza, 440026, Russia

参考

  1. Российское кардиологическое общество. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 4103. [Russian Society of Cardiology. Acute myocardial infarction with ST segment elevation electrocardiogram. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(11): 4103. (in Russ.)]. doi: 10.15829/29/1560-4071-2020-4103.
  2. Барбараш О.Л., Дупляков Д.В., Затейщиков Д.А. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021; 26(4): 4449. [Barbarash O.L., Duplyakov D.V., Zateyshikov D.A. and others. Acute coronary syndrome without ST segment elevation electrocardiogram. Clinical guidelines 2020. Russian Journal of Cardiology. 2021; 26(4): 4449. (in Russ.)] doi: 10.15829/1560-4071-2021-4449
  3. Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318(7200): 1730-1737. doi: 10.1136/bmj.318.7200.1730
  4. Szummer K, Wallentin L, Lindhagen L, et al. Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014. Eur Heart J. 2018;39(42):3766-3776. doi: 10.1093/eurheartj/ehy554
  5. Szummer K, Wallentin L, Lindhagen L, et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. Eur Heart J. 2017;38(41):3056-3065. doi: 10.1093/eurheartj/ehx515
  6. Golla MSG, Shams P. Heart Failure With Preserved Ejection Fraction (HFpEF). In: StatPearls. Treasure Island (FL): StatPearls Publishing; March 19, 2024.
  7. Kaddoura R, Patel A. Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction. Curr Probl Cardiol. 2023; 48(12): 102015. doi: 10.1016/j.cpcardiol.2023.102015
  8. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018; 39(1): 26-35. doi: 10.1093/eurheartj/ehx564
  9. Fukuta H, Goto T, Wakami K, et al. Effect of beta-blockers on heart failure severity in patients with heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev. 2021;26(1):165-171. doi: 10.1007/s10741-020-10013-5
  10. Arnold SV, Silverman DN, Gosch K, et al. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC Heart Fail. 2023;11(8 Pt 1):893-900. doi: 10.1016/j.jchf.2023.03.017
  11. Munkhaugen J, Ruddox V, Halvorsen S, et al. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. Am Heart J. 2019;208:37-46. doi: 10.1016/j.ahj.2018.10.005
  12. Rossello X, Raposeiras-Roubin S, Latini R, et al. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):291-301. doi: 10.1093/ehjcvp/pvab060
  13. Sean van Diepen, Sigrun Halvorsen, Venu Menon, The REDUCE-AMI trial: an important step in cardiovascular drug de-prescription, European Heart Journal. Acute Cardiovascular Care. 2024; 13 (4): 370–372. doi: 10.1093/ehjacc/zuae049.
  14. Kristensen AMD, Bovin A, Zwisler AD, et al. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. Trials. 2020; 21(1): 415. doi: 10.1186/s13063-020-4214-6
  15. Silvain J, Cayla G, Ferrari E, et al. βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial. Am Heart J. 2023; 258: 168-176. doi: 10.1016/j.ahj.2023.01.014
  16. Joo SJ, Kim SY, Choi JH, et al. Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021; 7(6): 475-482. doi: 10.1093/ehjcvp/pvaa029
  17. Dondo TB, Hall M, West RM, et al. β-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol. 2017; 69(22): 2710-20. doi: 10.1016/j.jacc.2017.03.578
  18. Wahlberg K, Arnold ME, Lustgarten D, et al. Effects of a Higher Heart Rate on Quality of Life and Functional Capacity in Patients With Left Ventricular Diastolic Dysfunction. Am J Cardiol. 2019;124(7):1069-1075. doi: 10.1016/j.amjcard.2019.07.008
  19. Российское кардиологическое общество. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11):4083. [Russian Society of Cardiology. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(11):4083 (in Russ.)]. doi: 10.15829/1560-4071-2020-4083.
  20. Horiuchi Y, Tanimoto S, Aoki J, et al. Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction. Int J Cardiol. 2016;221:765-769. doi: 10.1016/j.ijcard.2016.07.123
  21. Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14(2):219-225. doi: 10.1093/eurjhf/hfr161
  22. Закиев В.Д., Воробьёва Н.М., Малая И.П. и др. Бета-блокаторы при хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка: возможен ли депрескрайбинг? Рациональная Фармакотерапия в Кардиологии. 2023;19(6):607-613. [Zakiev V.D., Vorobyeva N.M., Malaya I.P. and others. Beta blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible? Rational Pharmacotherapy in Cardiology. 2023;19(6):607-613 (in Russ.)]. doi: 10.20996/1819-6446-2023-2987.
  23. Palau P, Seller J, Domínguez E, et al. Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction [published correction appears in J Am Coll Cardiol. 2022 Mar 1;79(8):848. doi: 10.1016/j.jacc.2022.01.012]. J Am Coll Cardiol. 2021;78(21):2042-2056. doi: 10.1016/j.jacc.2021.08.073
  24. M Seo, T Watanabe, T Yamada, et al. The clinical relevance of quality of life in patients with acute decompensated heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF Registry, European Heart Journal. 2022: 43 (2): 1059. doi: 10.1093/eurheartj/ehac544.1059
  25. Silverman DN, Plante TB, Infeld M, et al. Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial. JAMA Netw Open. 2019; 2(12): e1916598. doi: 10.1001/jamanetworkopen.2019.16598
  26. Frenneaux MP. Autonomic changes in patients with heart failure and in post-myocardial infarction patients. Heart. 2004;90(11):1248-1255. doi: 10.1136/hrt.2003.026146
  27. Saleem S, Khandoker AH, Alkhodari M, et al. Investigating the effects of beta-blockers on circadian heart rhythm using heart rate variability in ischemic heart disease with preserved ejection fraction. Sci Rep. 2023; 13(1):5828. doi: 10.1038/s41598-023-32963-0
  28. Troels Yndigegn, M.D., Bertil Lindahl, Ph.D., Katarina Mars, M.D., et al. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. April 7, 2024 N Engl J Med 2024;390:1372-1381 doi: 10.1056/NEJMoa2401479.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Eco-Vector,



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г
.